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Summary
Objective: The main objective of the study was to assess the impact of a community-based
delivery system of intermittent preventive treatment (IPT) for malaria in pregnancy with
sulfadoxine—pyrimethamine (SP) on access, parasitemia, anemia and low birth weight as primary
outcome measures.
Methods: A study was designed to test the community-based delivery system of IPT through
traditional birth attendants (TBAs), drug-shop vendors (DSVs), community reproductive health
workers (CRHWs) and adolescent peer mobilizers (APMs), and to compare these with IPTat health
units in an area of high malaria transmission — Mukono District, Uganda.
Results: Two thousand seven hundred and eighty-five pregnant women participated in the study.
The majority of the women (92.4%) at the community-based approaches received their first dose
of IPT during their second trimester compared to 76.1% at health units ( p < 0.0001). At both
health units and the community-based approaches, IPT increased mean hemoglobin by 6.7%
(p < 0.0001) for all parities and by 10.2% among primigravidae. IPT reduced the prevalence of
severe anemia from 5.7% to 3.1% (p < 0.04). The prevalence of parasitemia was reduced from
24.5% to 16.1% ( p < 0.001), and parasite density reduced significantly ( p < 0.02) after the first
dose and remained stable with the second dose. Overall the proportion of low birth weight was
6.3% (8.3% at health units versus 6.0% at the community-based approaches, p < 0.03) highlighting
the importance of access and adherence to IPT. This intervention was acceptable to 89.6% of the
women at the community-based approaches intending to use IPT in the future, while 48.1% of
them had recommended it to other women.
Conclusions: The community-based approaches increased access and adherence to IPT with
an effect on anemia, severe anemia, parasitemia and low birth weight. However the reduced
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effect of IPT on parasitemia points to drug resistance with SP and this requires further evaluation;
research into the identification of other more efficacious drugs for malaria prevention in pregnancy is
also required.
# 2007 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.Introduction
In Africa, malaria is highly endemic and is the leading cause of
morbidity and mortality. It contributes 4—19% to low birth
weight, 3—15% to maternal anemia, and 3—8% to infant
deaths, while maternal anemia contributes 7—18% to low
birth weight.1—3 The impact of malaria prevention in preg-
nancy using chemoprophylaxis with routine anti-malarial
drugs and intermittent preventive treatment (IPT) with sul-
fadoxine—pyrimethamine (SP) is well documented.1,4—6 IPT
with SP has been shown to reduce malaria episodes, maternal
parasitemia, anemia, and the incidence of low birth
weight.2,5,7—15 The beneficial effects of IPT are more
pronounced among primigravidae and secundigravidae as
compared to multigravidae women.13,16,17 In Kenya, it was
demonstrated that IPT with SP could reduce severe anemia
among primigravidae by 39%.7 As a result of these studies, the
World Health Organization (WHO) recommends that all preg-
nant women living in malaria endemic areas be given malaria
chemoprophylaxis or IPT with SP.18
Despite implementation of IPT, poor accessibility and use
are reported. In Malawi, although 90% of the pregnant women
knew that SP was recommended during pregnancy, only 36%
received the recommended two-dose regimen.19 Similarly, in
Kenya, despite 96% of the providers being aware of IPTwith
SP, only 5% of the pregnant women received SP and con-
straints in commodity supply and high costs of accessing
services were cited.20 Elsewhere, low use and adherence
to IPT has also been attributed to late antenatal care atten-
dance.21
Data on community-based approaches with IPT are lim-
ited. In Kenya and The Gambia, village health volunteers and
traditional birth attendants (TBAs) provided malaria chemo-
prophylaxis to pregnant women and were successful in redu-
cing malaria episodes and parasitemia, and increasing birth
weight of babies and maternal hemoglobin levels.22—24 How-
ever, these studies were randomized and did not assess how
these resource persons could provide chemoprophylaxis
under a normal health-seeking behavior pattern. We
designed a study to assess a community-based delivery of
IPT for malaria prevention in pregnancy through TBAs, drug
shop vendors (DSVs), adolescent peer mobilizers (APMs) and
community reproductive health workers (CRHWs). The main
objective of the study was to assess the effect of this novel
delivery system on access and use of IPT, and its effect on
maternal parasitemia, anemia and low birth weight.
Materials and methods
Study area and population
The study was implemented in Mukono District, in central
Uganda. The background characteristics of the study area
have been published elsewhere.25,26 Briefly the districtexperiences high temperatures and heavy rainfall during
the months of March to May and October to November. This
district was selected because most areas in the district are
hyperendemic for malaria while areas on the shores of Lake
Victoria are holoendemic and experience perennial transmis-
sion levels.
The intervention study
The study was implemented in 25 parishes randomly selected
from nine rural sub-counties bordering the lakeshore region
of the district. The intervention was implemented in 21
parishes while IPTat health units (control) was implemented
in four parishes. A parish has approximately 2000 people. The
intervention consisted of training community resource per-
sons (13 APMs, 14 CRHWs, 14 TBAs, and 10 DSVs) to distribute
IPT. The community resource persons were trained for one
week by personnel from the district health office, together
with the research team, in the following areas: dangers of
malaria in pregnancy, malaria prevention interventions, the
benefits of SP and its side effects, taking blood samples for
parasite count/hemoglobin analysis, and taking the baby’s
weight and estimating the gestational age. One of the key
components of the intervention study was a community
mobilization and sensitization campaign to ensure that all
women received information on the intervention and knew
where to get the SP.
Three health centers — Seeta-Namuganga, Kattogo,
Seeta-Nazigo — and Kawolo District Hospital were selected
from a list of health units in the study area to provide the
control group for routine provision of IPT. The criterion for
selecting a health unit was its ability to provide IPT. The
health workers received explanations on the study and its
objectives. The health units received routine supervision by
project and district personnel.
The pregnant women who exclusively accessed IPT (both
the first and second dose of SP) at the four health units
constituted the control group, while pregnant women who
accessed IPT at the new approaches constituted the inter-
vention group.
Recruitment of pregnant women
All pregnant women who consented to participate in the
study were given SP (500 mg sulfadoxine + 25 mg pyrimetha-
mine) during the second and third trimester of their preg-
nancy as a directly observed therapy (DOT), as recommended
by the policy in Uganda.27 The date for receiving the second
dose of SP was discussed, agreed upon, and written on a card.
Women took this card with them to wherever they went to
get care. The weight of babies delivered at home was taken
within five days of delivery. Baby weighing scales (UNICEF-
Super Samson Salter) measuring to the nearest 50 g were
used. Women were encouraged to inform the resource per-
sons as soon as they delivered their babies. Women who
24 A.K. Mbonye et al.presented in the first trimester were given an appointment to
come back. Exclusion criteria were: pregnant women who
refused to give consent to the study and those who gave a
history of allergy to sulfonamide-containing drugs. Pregnant
women also received iron and folic acid supplementation, de-
worming with mebendazole (100 mg tablets), and informa-
tion on nutrition.
Laboratory methods
The protocol required that three blood samples be taken
from each pregnant woman, one at recruitment before
receiving the first dose of SP, the second sample before
receiving the second dose of SP, and the third at 36 weeks
of gestation or at delivery. Hemoglobin (Hb) was measured
using a HaemoCue1 photometer (Angelholm, Sweden).
Thick blood smearswere prepared and examined at a labora-
tory of the Vector Control Division, Ministry of Health in
Kampala. Blood smears were stained using Giemsa stain and
parasites were counted against 100 leukocytes and
expressed as number of parasites/ml of blood assuming a
standard leukocyte count of 8000/ml of blood. A blood smear
was regarded as negative following the examination of a
minimum of 100 high power fields with no parasites seen.
Parasite density was calculated as mean geometric mean
parasite density (GMPD/ml). Quality control was ensured by
re-examination of a randomly selected 10% sample of all
slides by another technician to confirm the accuracy of the
results. All buffers, solutions and stains were stored appro-
priately and cleanliness and sterility of equipment main-
tained. To ensure accuracy in measurements, a laboratory
technician provided regular support to the resource persons,
and the batteries for the HaemoCueswere regularly checked
and replaced.
Statistical analyses
Data were entered into EpiInfo version 6.0 (CDC, Atlanta, GA,
USA), cleaned and transferred to Stata version 8.2 (Stata
Corp., College Station, Texas, USA) for analysis. A t-test was
used to study the differences in Hb and birth weight between
the health units and the community-based approaches, while
one-way analysis of variance (ANOVA) was used to assess
variations among the community-based approaches. A paired
t-test was used to assess differences in repeated measure-
ments of Hb and birth weight to assess the impact of the two
successive doses of SP. The Kruskall—Wallis rank test and the
Spearman’s rank correlation test were used to compare
parasite density between the health units and the commu-
nity-based approaches. Risk ratios were computed for ane-
mia, parasitemia and low birth weight for both the health
units and the community-based approaches, and the protec-
tive efficacy of IPT calculated as 100  (1  risk ratio)
together with the 95% confidence intervals. In assessing
the impact of IPT at the health units and the community-
based approaches, the effect of potential confounding
variables (parity, education, and gestational age) were
controlled for using the Mantel—Haenszel technique, com-
paring adjusted and crude risk ratios. For all the analyses,
crude and adjusted ratios showed no evidence of confound-
ing; hence the risk ratios presented are unadjusted ratios.
Values of p less than 0.05 were considered significant. Anemiawas defined as Hb less than 11.0 g/dl, severe anemia as Hb
less than 7.0 g/dl.
Evaluation study
In order to study the acceptability and sustainability of the
community-based approaches a triangulation of quantitative
(survey) and qualitative techniques (key informant inter-
views) were used to collect data. A semi-structured ques-
tionnaire containing closed and open-ended questions was
administered to 1321 (47.4%) randomly selected women out
of 2785 who participated in the study. Key informant inter-
views (KIs) were conducted after the intervention, among the
resource persons, health workers, women who had partici-
pated in the intervention, and opinion leaders since they
were regarded to be more knowledgeable on health-related
matters in their community. In total, 60 KIs were conducted.
Data were collected along the following thematic lines:
acceptability of the community-based approaches and their
sustainability. Data were manually analyzed along the
defined themes.
Ethical issues
The study was approved by the Danish National Committee
for Biomedical Research Ethics and the Uganda National
Council of Science and Technology. Verbal consent was
obtained from all women and key informants who partici-
pated in the study. Sterile needles and syringes were used to
draw blood from mothers. Women were informed of the
laboratory examination results. They also received explana-
tions on the benefits of SP and the possible adverse effects in
pregnancy. It was also explained to the women that they were
free to withdraw from the study at any time and that they
would have access to SP again if they wished. All malaria
cases and other diseases that arose during pregnancy were
referred to health units for treatment.
Results
Study population
A total of 2785 women participated in the study. The mean
age of all women was 23.9 years (range 14—46 years). There
was no difference in the mean age of women accessing IPTat
health units (controls, 23.6 years) and the new approaches
(intervention, 24.0 years) ( p > 0.12).
Interestingly, the community-based approaches increased
access and use of IPT. Women at the community-based
approaches received IPT earlier, around 21.0 weeks (range
20.7—21.1) gestation versus 23.0 weeks gestation (range
22.7—23.4) at health units ( p < 0.0001). The majority of
women (92.4%) at the community-based approaches received
their first dose of IPT during the second trimester as recom-
mended by the policy in Uganda compared to 76.1% at health
units ( p < 0.0001). Similarly there was high adherence to
the recommended two doses of SP with the community-
based approaches — 67.5% versus 39.9% at health units
( p < 0.0001).
In order to have comparable groups at the health units
and the community-based approaches, we calculated the
number of women who exclusively accessed IPT at each
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at the same delivery point). The majority of women acces-
sing the health units, 190/281 (67.6%), had exclusively
accessed IPT at health units, while of those accessing the
community-based approaches, 1209/1404 (86.1%) had
exclusively accessed IPT at the community-based
approaches. The proportion of women who exclusively
accessed IPT at the different community-based approaches
was highest with CRHWs (87.7%, 370/422 women), APMs
(85.7%, 257/300 women), TBAs (81.9%, 322/393 women),
and DSVs (85.5%, 260/304 women). Hence, women visiting
each SP delivery point were comparable. Thus 2785 women
were enrolled in the study and received the first dose of SP.
Of these, 1685 received the second dose of SP while 1100 did
not return for the second dose. Of those who received the
second dose, 190 and 1209 women exclusively received this
fromhealth units and the newapproaches, respectively. Few
pregnant women, 286 (17.0%) received SP from both
sources.
The effect of intermittent preventive treatment
on peripheral parasitemia
Thick blood smears were taken from 2344 (84.2%) of the
pregnant women at recruitment. Five hundred and seventy-
three women (24.5%) were positive for Plasmodium falci-
parum parasites, 124/559 (22.2%) at health units and 449/
1785 (25.2%) at the community-based approaches
( p > 0.15). After the first dose of SP, thick blood smears
were taken from 1132 pregnant women and 180 (15.9%) were
positive for Plasmodium falciparum parasites; 12/113
(10.6%) were recorded at health units and 168/1019
(16.5%) at the community-based approaches.
As seen in Table 1, parasitemia among all women
decreased from 24.5% at recruitment to 15.9% after the first
dose of SP ( p < 0.001).
After the second dose of SP, thick blood smears were taken
from 652 pregnant women. Overall, parasitemia was found inTable 1 The effect of intermittent preventive treatment on per
Variable All subjects a
Positive smear at baseline 573 (24.5%)
Positive smear after one dose of SP 180 (15.9%)
Positive smear after two doses of SP 105 (16.1%)
Protective efficacy with 95% CI
Efficacy of one dose of SP
Efficacy of two doses of SP
IPT, intermittent preventive treatment; SP, sulfadoxine—pyrimethamin
a Baseline N = 2344, following first dose N = 1350, following second d
b Baseline N = 559, following first dose N = 113, following second dos
c Baseline N = 1782, following first dose N = 1019, following second d105/652 women (16.1%), 3/33 women (9.1%) from the health
units and 102/619 (16.5%) from the community-based
approaches ( p < 0.04).
At recruitment, parasite density was slightly higher among
women at community-based approaches compared to those
at health units ( p > 0.3). Parasite density was highest among
primigravidae compared to multigravidae ( p < 0.0001).
After the first dose of SP, parasite density for all women
decreased ( p < 0.02) but no further reduction was seen after
the second dose ( p > 0.17).
The effect of use of insecticide treated nets (ITNs) on
parasitemia was assessed. At baseline, the use of ITNs among
women who accessed SP at health units was higher (12.1%,
85/703) than among those using the community-based
approaches (7.7%, 160/2078) ( p < 0.0001), although this
was not associated with peripheral parasitemia ( p > 0.7).
At delivery, the use of ITNs was not statistically different
among women at health units (15.7%, 18/115) compared to
the community-based approaches (17.3%, 163/942)
( p > 0.7), nor was it associated with peripheral parasitemia
( p > 0.6).
The first dose of SP had 40% protective efficacy on para-
sitemia at health units and 20% at the community-based
approaches. However, the second dose of SP had a slightly
lower protective efficacy of 30% at the health units and 10% at
the community-based approaches (Table 1).
Using analysis of repeated measures, we assessed para-
sitemia among 990 women who had negative smears at
recruitment and received SP. One hundred and forty-five
(14.7%) had positive smears when they came for the second
dose of SP. Of the 427 women who had negative smears
after the first dose, 62 (14.5%) had positive smears at 36
weeks of gestation or at delivery. We also analyzed
the effect of IPT on parasitemia among 340 women who
had positive smears at recruitment. Seventy-four (21.8%)
still had positive smears when they came for the second
dose of SP, and 8/33 (24.2%) had parasitemia after the
second dose.ipheral parasitemia
Pregnant women
accessing IPT at
health unitsb
Pregnant women
accessing IPT at
the community
based approachesc
p-Value
124 (22.2%) 449 (25.2%) p > 0.15
12 (10.6%) 168 (16.5%) p < 0.04
3 (9.1%) 102 (16.5%) p < 0.04
40% 20%
RR = 0.6 (0.4—1.1) RR = 0.8 (0.6—1.2)
p > 0.2 p > 0.28
30% 10%
RR = 0.7 (0.4—0.9) RR = 0.9 (0.5—1.2)
p < 0.01 p > 0.4
e.
ose N = 652.
e N = 33.
ose N = 619.
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on anemia
Blood samples for Hb analyses were collected from 761
(27.3%) pregnant women at recruitment, 389/1683 (23.1%)
women after the first dose of SP, and 228/1689 (13.5%) after
the second dose. At recruitment, mean Hb for all parities was
(10.5 g/dl, 95% CI 10.3—10.6). Women accessing IPTat health
units had a slightly higher mean Hb, 10.6 g/dl compared to
10.3 g/dl at the community-based approaches ( p > 0.09).
The proportion of anemic women at the community-based
approaches was higher compared to that of women at health
units, p < 0.02. The proportion of severely anemic women
was also slightly higher among women who accessed IPT at
the community-based approaches ( p > 0.3). After the first
dose of SP, the proportion of anemia and severe anemia
decreased at both health units and the community-based
approaches. IPT reduced the prevalence of severe anemia
from 5.7% to 3.1% ( p < 0.04) following the first dose. The
second dose of SP did not lead to a further reduction of
anemia at either the health units or the community-based
approaches (Table 2).
At recruitment, mean Hb for all parities was 10.5 g/dl
(95% CI 10.3—10.6); this increased to 11.0 g/dl (95% CI 10.9—
11.3) after the first dose of SP ( p < 0.001), and stabilized at
11.0 g/dl (95% CI 10.7—11.4) after the second dose ( p > 0.6).
Overall IPT increasedmean Hb by 6.7%. Primigravidae had theTable 2 The effect of intermittent preventive treatment on ane
Variable All subjects a
Mean Hb at recruitment (g/dl) 10.5 (10.3—10
Anemia (Hb < 11.0 g/dl) 431 (56.6%)
Severe anemia (<7.0 g/dl) 43 (5.7%)
Mean Hb after the first dose of SP 11.0 (10.9—11
Anemia (Hb <11.0 g/dl) 164 (42.2%)
Severe anemia (<7.0 g/dl) 12 (3.1%)
Mean Hb after the second dose of SP 11.0 (10.7—11
Anemia (Hb <11.0 g/dl) 97 (42.5%)
Severe anemia (<7.0 g/dl) 16 (7.0%)
Protective efficacy with 95% CI
Efficacy of one dose of SP on anemia
Efficacy of two doses of SP on anemia
Efficacy of one dose of SP on severe anemia
Efficacy of two doses of SP on severe anemia
IPT, intermittent preventive treatment; Hb, hemoglobin; SP, sulfadoxi
a Baseline N = 761, following first dose N = 389, following second dos
b Baseline N = 446, following first dose N = 150, following second dos
c Baseline N = 315, following first dose N = 214, following second doslowest mean Hb, 9.8 g/dl, compared to other parities (Hb
10.7 g/dl, p < 0.0001). After the first dose of SP, mean Hb
among primigravidae increased significantly to 10.4 g/dl
( p < 0.001) and to 10.8 g/dl ( p < 0.02) after the second
dose. Thus IPT increased Hb by 10.2% among primigravidae.
For multigravidae, mean Hb increased from 10.7 g/dl at
recruitment to 11.3 g/dl after the first dose of SP
( p < 0.001), but increased no further with the second dose
( p > 0.33).
SP was more protective for anemia and severe anemia at
the community-based approaches compared to health units.
The two doses of SP had a 10% protective efficacy on anemia
at health units and 20% at the community-based approaches.
The two doses of SP had a 40% efficacy on severe anemia at
the community-based approaches with no effect at health
units. These results seem to be affected by the small numbers
of anemia and severe anemia recorded at each approach and
hence the wide confidence intervals (Table 2).
The effect of intermittent preventive treatment
on low birth weight
Birth weight was determined for 1227 babies. Themajority of
the babies, 986 (80.4%), were weighed within one day of
delivery, 164 (13.4%) were weighed within five days, and 77
(6.3%) were weighed after five days. Analysis was carried out
on 1098 babies who were full term, singleton, and had beenmia
Pregnant women
accessing IPT at
health units b
Pregnant women
accessing IPT at
community based
approachesc
p-Value
.6) 10.6 (10.4—10.8) 10.3 (10.1—10.6) p > 0.09
236 (52.9%) 195 (61.9%) p < 0.02
22 (4.9%) 21 (6.7%) p > 0.3
.3) 11.0 (10.6—11.3) 11.2 (10.9—11.4) p > 0.6
69 (46.0%) 95 (44.6%) p > 0.07
6 (4.0%) 6 (2.8%) p > 0.4
.4) 10.8 (9.9—11.6) 11.0 (10.7—11.5) p > 0.6
17 (34.7%) 80 (44.7%) p < 0.04
4 (11.4%) 12 (6.2%) p > 0.4
Not protective 4%
RR = 1.03 (0.8—1.3) RR = 0.96 (0.8—1.2)
p > 0.8 p > 0.2
10% 20%
RR = 0.9 (0.6—1.4) RR = 0.8 (0.6—1.3)
p > 0.55 p > 0.28
Not protective 30%
RR = 1.4 (0.5—4.3) RR = 0.7 (0.2—0.8)
p > 0.5 p < 0.02
Not protective 40%
RR = 1.6 (0.6—4.6) RR > 0.6 (0.2—1.8)
p > 0.8 p > 0.4
ne—pyrimethamine.
e N = 228.
e N = 35.
e N = 193.
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twenty-five (47.8%) of the babies were male, and mean birth
weight was not different by sex ( p > 0.11). The overall mean
birth weight was 3220 g (range 3186—3264); it was 3201 g
(range 3030—3236) at health units and 3223 g (range 3186—
3264) at the community-based approaches ( p > 0.7;
Table 3).
The proportion of low birth weight for all babies was 6.3%
(69/1098); it was 8.3% (12/145) at health units and 6.0% (57/
953) for babies at the community-based approaches
( p < 0.03). The proportion of low birth weight for all women
who received one dose of SP was 7.6% (16/210); it was 10.3%
(6/58) at health units and 6.6% (10/152) at the new
approaches ( p > 0.3).
Women who received the second dose had a slightly lower
proportion of low birth weight babies than for the first dose —
6.0% (45/750) ( p > 0.2). Of those receiving the second dose,
low birth weight was found in 4/51 (7.8%) babies at health
units and 41/707 (5.8%) at the community-based approaches
( p > 0.7; Table 3). The women who received one dose of SP
had a lower protective efficacy of 4% on low birth weight at
the health units, compared to 10% with the community-based
approaches. Two doses of SP more than doubled the protec-
tive efficacy on low birth weight at both health units and the
community-based approaches (Table 3).
Acceptability and sustainability of the
community-based approaches
The factors that enabled women to access the first dose of SP
were explored. The main reason (80% of the responses) that
compelled women (both at health units and the community-
based approaches) to access IPT was their previous experi-
ences with malaria. The women said they wanted to get rid of
malaria and gain more energy since malaria in pregnancy
makes them weak, and 7% of them said that they wanted to
produce healthy babies. Women accessed the second dose of
SP due to improved health with the first dose. The beneficialTable 3 The effect of intermittent preventive treatment on low
Variable All subjects a
Mean birth weight (grams) 3220 (3186—3264)
Proportion of low birth weight 69 (6.3%)
Low birth weight with one dose of SP 16 (7.6%)
Low birth weight with two doses of SP 45 (6.0%)
Protective efficacy with 95% CI
Efficacy of one dose of SP
Efficacy of two doses of SP
IPT, intermittent preventive treatment; SP, sulfadoxine—pyrimethamin
a Baseline N = 1098, following first dose N = 210, following second do
b Baseline N = 146, following first dose N = 58, following second dose
c Baseline N = 950, following first dose N = 152, following second doseffects of SP were mentioned by 63% of the women (both at
health units and the community-based approaches) who said
they felt stronger and healthier and that they experienced
reduced episodes of malaria.
A third of the women said it was easy for them to parti-
cipate in the study because SP was free in addition to their
blood being checked for malaria parasites. Eighty-four per-
cent of women at the community-based approaches thought
that giving them the results of the blood tests on malaria was
very good because they got to know whether or not they had
parasites even in the absence of signs of malaria such as fever
or headaches.
Sixty-six percent of the women who accessed SP at the
community-based approaches expressed satisfaction that
they had acquired adequate knowledge on malaria preven-
tion in pregnancy with IPTand malaria prevention in general.
Sixty-two percent of the women thought that because of the
awareness due to the intervention, their health-seeking
behavior had changed and they would always seek care for
malaria prevention with IPT and ITNs during any subsequent
pregnancies.
One important aspect for the sustainability of this
approach is its acceptability and the future intention for
the use of IPT. The majority of women at the community-
based approaches (844/942, 89.6%) and those at health units
(147/174, 84.5%) intended to use IPT in their subsequent
pregnancies. Similarly, 71/172 (41.3%) of the women at
health units and 450/936 (48.1%) of those at community-
based approaches had already recommended IPT to other
women.
Another important factor for the sustainability of this
approach was the trust the women had in the resource
persons. Most women who had accessed SP from TBAs and
DSVs trusted them because these were their common source
of care. Eighty-four percent of the women described the
resource persons as easily accessible, approachable, kind and
understanding. Forty percent said the resource persons gave
good and convincing explanations on IPT, especially thosebirth weight
Pregnant women
accessing IPT
at health unitsb
Pregnant women
accessing IPT at
the community
based approachesc
p-Value
3201 (3030—3236) 3223 (3186—3264) p > 0.7
12 (8.3%) 57 (6.0%) p < 0.03
6 (10.3%) 10 (6.6%) p > 0.3
4 (7.8%) 41 (5.8%) p > 0.4
4% 10%
RR = 0.96 (0.7—1.5) RR = 0.9 (0.6—1.6)
p > 0.48 p > 0.37
10% 26%
RR = 0.9 (0.2—1.1) RR = 0.74 (0.3—1.9)
p > 0.7 p > 0.6
e.
se N = 750.
N = 51.
e N = 706.
28 A.K. Mbonye et al.with CRHWs and APMs, while 30%, especially those at DSVs
and TBAs, said they trusted the resource persons. The women
who accessed IPT at health units said they got SP because
they were attending for routine antenatal care, and they had
confidence in the health workers who they thought would
manage complications of pregnancy and were knowledgeable
on health matters.
The involvement of the local council leaders was men-
tioned by most key informants. Local councils encouraged
women to access IPT and they were involved in mobilization
and increasing awareness. Involvement of the local leaders
was an important aspect for the sustainability of this
approach.
Discussion
This study assessed whether novel community-based
approaches could increase access and adherence to IPTwith
an effect on maternal parasitemia, anemia and low birth
weight as previous studies have reported.8—10,12 Our results
show that the community-based approaches increased access
to IPT and had an effect on the prevalence of anemia,
parasitemia and low birth weight. There were variations of
this effect between women who accessed IPTat health units
and the community-based approaches, indicating the impor-
tance of access and adherence to IPT.
Increased access and adherence to IPTwas attributed to
easily accessible and trusted resource persons who could
make home visits and follow up on their clients. It was
also attributed to the explanations on the impact of
malaria in pregnancy, the perceived benefits of SP in
pregnancy, and the demystifying of misconceptions on
the use of SP in pregnancy by the resource persons. It is
important to note that the resource persons are currently
engaged in other health promotion activities like provision
of health education, nutrition and promoting use of ITNs. It
is possible that women benefited from these services in
addition to IPT. Similarly women who accessed IPT at
health units had a lower proportion of parasitemia com-
pared to those at the new approaches. This is probably
because, in addition to IPT, these women accessed effec-
tive case treatment of malaria and other illnesses at the
health units.
Of concern with the involvement of community resource
persons and community leaders in longitudinal studies, is
how to motivate and retain them. In this study, after
training, the resource persons were given certificates,
regular meetings were held with them to solve problems,
and technical support was provided. Bicycles were provided
to facilitate home visits and follow-up of women. These
aspects helped to motivate and retain them. There was
constant interaction between the research team and the
community leaders to explain the progress of the study and
to elicit their commitment. The resource persons also
interacted with these leaders during the course of the
study. However one CRHW got a job and left, one APM
returned to school, and one other APM and one TBA died
during the course of the study.
Our data show that after the first dose of IPT, there was a
reduction in prevalence of peripheral parasitemia and para-
site density among women of all parities, but no further
effect was obtained with the second dose. Further to this,some women who had negative smears at recruitment were
parasitemic at the time of the second dose, and some of those
who had negative smears after the first dose were parasite-
mic after completing two doses. Although this observation
could be due to re-infection in between the doses of SP, drug
resistance may play a part; this argument is supported by
reports of high drug resistance to SP in Uganda.28—30 Drug
resistance could have been responsible for the lesser effect
of the second dose of SP on parasitemia at both health units
and the community-based approaches. It seems the first dose
of SP cleared most of the parasites but some developed
resistance rendering the second dose ineffective. This could
explain the lesser impact of the second dose on parasitemia,
anemia and severe anemia. We suggest a study to evaluate
this aspect further.
These results compare well with findings reported earlier
in Malawi5 and Kenya.7 Interestingly the proportion of low
birth weight observed in our study (6.3%) is lower than that
reported in Malawi, after one and two doses of SP (13.3% and
10.3%, respectively), probably due to the difference in
malaria transmission levels, levels of drug resistance to SP,
socioeconomic levels, and HIV prevalence in the two popula-
tions. The proportion of low birth weight observed in our
study is much lower than that reported in an earlier study in
the same area (16.0%) before IPT.31 Although the low birth
weight in this present study cannot be attributed to IPT
alone, we advocate optimizing access to IPT with the com-
munity-based approaches.
This study did not measure the prevalence of placenta
parasitemia, which is a sensitive indicator of malaria in
pregnancy.4,17 This was because involving community
resource persons in high levels of laboratory work would
not yield accurate results and could lead to fatigue and their
non-involvement. Measurement of this parameter could have
given a lot of insight into the effect of IPT on prevalence of
placental parasitemia in this area of high malaria transmis-
sion where parasite resistance has been reported. We recom-
mend a further study to assess the efficacy of SP in pregnancy
at a community level, which measures placental parasitemia
as well as evaluation of other drug combinations for malaria
prevention in pregnancy.
These findings have several policy implications for
malaria prevention in pregnancy. If the policy allows the
community-based approaches to distribute IPT, then
resource persons will have to be trained, facilitated and
linked to the health units to get SP basic supplies. It will
probably be more cost-effective to have an integrated
system linking the resource persons to nearby health units
to collect SP and for effective supervision. This strategy
will require addressing the issue of understaffing at health
units and the frequent stock-outs of essential drugs like
SP for the sustainability of this approach. Another possible
programming option is to improve quality of care at
health units, especially ensuring availability of essential
supplies/drugs, while involving the resource persons in the
community sensitization and promotion of IPT. This could
possibly improve use of other healthcare services in addi-
tion to malaria treatment and prevention. Finally there is a
need to evaluate the effectiveness of SP for IPT since
resistance to this drug is on the increase. A search for
more efficacious drugs or a combination of them is there-
fore necessary.
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